, Tracking Stock Market Picks
Enter Symbol:
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

up 105.19 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy with price target $11 by Roth Capital

Posted on: Thursday,  Feb 25, 2010  1:25 PM ET by Roth Capital

Roth Capital rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 02/25/2010. Previously Roth Capital rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on
12/23/2009., when the stock price was $3.66. Since then, Achillion Pharmaceuticals, Inc. has gained 105.19% as of 10/07/2015's recent price of $7.51.
If you would have followed the previous Roth Capital's recommendation on ACHN, you would have gained 105.19% of your investment in 2114 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/25/2010 1:25 PM Buy
2.27 11.00
as of 12/31/2010
1 Week up  18.40 %
1 Month up  50.69 %
3 Months up  42.71 %
1 YTD up  38.58 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/23/2009 8:25 AM Buy
3.66 12.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy